AA randomized prospective controlled trial of long-acting muscarinic antagonist and long-acting be-ta2 agonist fixed dose combinations in patients with chronic obstructive pulmonary disease: Effects on quality of life and pulmonary function and preference - A randomized prospective controlled trial of long-acting muscarinic antagonist and long-acting be-ta2 agonist fixed dose combinations in patients with chronic obstructive pulmonary disease

o significant differences in CAT or mMRC were reported, and no significant difference in FEV1 was observed. Although FVC was higher after Ume/ Vil and Tio/ Olo administration, and MMF and V25 were higher after Gly/Ind administration, the differences reported were small. In the final comparative questionnaire survey, patients reported better actual feeling of being able to inhale following Gly/ Ind administration, although no significant differences in adverse events or other evaluations were reported.